Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification
Funds identifying and validating a disease target, then finding a preliminary drug, biologic or combination-product lead against it.
Before anyone can develop a therapy, something has to be identified as worth going after in the first place — a target whose biology actually explains the disease. This notice funds that identification step and the one right after it, as a single award.
It sits inside NHLBI's Catalyze Program, which exists to move basic discoveries toward diagnostic and therapeutic candidates ready for human test…
Phased target identification and validation (R61) followed by preliminary product or lead-series identification (R33) for small molecule, biologic and combination-product candidates against heart, lung, blood or sleep disease, under NHLBI's Catalyze Program.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up